Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 1998 Nov 2;188(9):1563–1573. doi: 10.1084/jem.188.9.1563

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

(A) ET1 plasma concentrations (fmol/ml) before and after a 5-d intravenous treatment with prednisolone (n = 17; 10 males and 7 females; mean age 51.3 yr). Before glucocorticoid treatment (mean ± SE): 0.58 ± 0.05; after 5 d glucocorticoid treatment: 0.89 ± 0.08; P < 0.014. (B) ET1 plasma concentrations before and after a 5-d intravenous treatment with diclofenac, tetrazepam, and tramadol but without prednisolone (n = 8; four males and four females; mean age 44.2 yr): pretreatment 0.43 ± 0.08 fmol/ml (mean ± SE); ET1 plasma concentration after 5 d treatment 0.44 ± 0.07 fmol/ml (P not significant).

(A) ET1 plasma concentrations (fmol/ml) before and after a 5-d intravenous treatment with prednisolone (n = 17; 10 males and 7 females; mean age 51.3 yr). Before glucocorticoid treatment (mean ± SE): 0.58 ± 0.05; after 5 d glucocorticoid treatment: 0.89 ± 0.08; P < 0.014. (B) ET1 plasma concentrations before and after a 5-d intravenous treatment with diclofenac, tetrazepam, and tramadol but without prednisolone (n = 8; four males and four females; mean age 44.2 yr): pretreatment 0.43 ± 0.08 fmol/ml (mean ± SE); ET1 plasma concentration after 5 d treatment 0.44 ± 0.07 fmol/ml (P not significant).